What we achieved

Commercialization of results from basic research since 2010

  • on average 10 awarded patents per year
  • 11 signed license agreements
  • 8 incubated projects in the area of treatment of cancer, CNS diseases, inflammation, infection and liver diseases; project iBodies

Selected partners

  • Merck Millipore – labeled nucleoside triphosphates transporting system for labeling DNA of living cells (already available on market as BioTracker™ NTP-Transporter Molecule)
  • Novo Nordisk – novel ways for the treatment of obesity and related diseases
  • SHINE Technologies – a novel technology for Lu-177 isolation

Licenses to spin-offs